| Target | Candidate | Indication | Discovery | Pre-clinical | Phase 1 / IIT | Phase 2 | Phase 3 | Rights |
|---|---|---|---|---|---|---|---|---|
| ITIL-168 Melanoma | ITIL-168 (Delta-1) | Melanoma | Initiation of Phase 2* trial | |||||
| ITIL-168 NSCLC | ITIL-168 + Pembro (Delta-2) | NSCLC | Global | |||||
| Optimized – HNSCC | ITIL-168 + Pembro (Delta-2) | HNSCC | Initiation of Phase 1 trial | |||||
| ITIL-168 Cervical Cancer | ITIL-168 + Pembro (Delta-2) | Cervical Cancer | Initiation of Phase 1 trial | |||||
PD-L1: Programmed death-ligand 1; VEGF: Vascular endothelial growth factor; Cytotoxic T-lymphocyte associated protein 4;